Metabolic markers GAPDH, PKM2, ATP5B and BEC-index in advanced serous ovarian cancer

BMC Clinical Pathology

Volumn 13, Issue 1, 2013, Pages

  Hjerpe, Elisabet ^a   Egyhazi Brage, Suzanne ^b   Carlson, Joseph ^a   Frostvik Stolt, Marianne ^b   Schedvins, Kjell ^a   Johansson, Hemming ^a   Shoshan, Maria ^b   Åvall Lundqvist, Elisabeth ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

ATP5B; BEC; GAPDH; Immunohistochemistry; Metabolic markers; Ovarian cancer; PKM2; Real time PCR

Indexed keywords

GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; MESSENGER RNA; PKM2 PROTEIN; PLATINUM DERIVATIVE; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; PYRUVATE KINASE; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BIOENERGETIC CELLULAR INDEX; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURGERY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVARY CANCER; OVERALL SURVIVAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RNA EXTRACTION;

EID: 84887705174     PISSN: None     EISSN: 14726890     Source Type: Journal    
DOI: 10.1186/1472-6890-13-30     Document Type: Article

References (27)

1. Carcinoma of the Ovary. Heintz APM, Odicino F, Maisonneuve P, Quinn MA, Benedet JL, Creasman WT, Ngan HYS, Pecorelli S, Beller U, Int J Gynecol Obstet 2006 95 Supplement 1 161 S192
2. Hallmarks of Cancer: The Next Generation. Hanahan D, Weinberg Robert A, Cell 2011 144 5 646 674
3. The Bioenergetic Signature of Cancer: A Marker of Tumor Progression. Cuezva JM, Krajewska M, de Heredia ML, Krajewski S, Santamaria G, Kim H, Zapata JM, Marusawa H, Chamorro M, Reed JC, Cancer Res 2002 62 22 6674 6681 (Pubitemid 35364137)
4. The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB, Cell Metab 2008 7 1 11 20
5. Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. Altenberg B, Greulich KO, Genomics 2004 84 6 1014 1020 (Pubitemid 39469126)
6. Identification of potential prognostic biomarkers for node-negative breast tumours by proteomic analysis: A multicentric 2004 national PHRC study. Descotes F, Jézéquel P, Spyratos F, Campion L, Grenot C, Lerebours F, Campone M, Guérin-Charbonnel C, Lanoe D, Adams M, et al. Int J Oncol 2012 41 1 92 104
7. Overexpression of the M2 isoform of pyruvate kinase is an adverse prognostic factor for signet ring cell gastric cancer. Lim JY, Yoon SO, Seol SY, Hong SW, Kim JW, Choi SH, Cho JY, World J Gastroenterol 2012 18 30 4037 4043
8. Pyruvate kinase type M2 is upregulated in colorectal cancer and promotes proliferation and migration of colon cancer cells. Zhou C-F, Li X-B, Sun H, Zhang B, Han Y-S, Jiang Y, Zhuang Q-L, Fang J, Wu G-H, IUBMB Life 2012 64 9 775 782
9. The bioenergetic signature of lung adenocarcinomas is a molecular marker of cancer diagnosis and prognosis. Cuezva JM, Chen G, Alonso AM, Isidoro A, Misek DE, Hanash SM, Beer DG, Carcinogenesis 2004 25 7 1157 1163 (Pubitemid 38968043)
10. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. Isidoro A, Casado E, Redondo A, Acebo P, Espinosa E, Alonso AM, Cejas P, Hardisson D, Fresno Vara JA, Belda-Iniesta C, et al. Carcinogenesis 2005 26 12 2095 2104 (Pubitemid 41672197)
11. Ovarian carcinoma cells with low levels of β-F1-ATPase are sensitive to combined platinum and 2-deoxy-d-glucose treatment. Hernlund E, Hjerpe E, Åvall-Lundqvist E, Shoshan M, Mol Cancer Ther 2009 8 7 1916 1923
12. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Hernlund E, Ihrlund LS, Khan O, Ates YO, Linder S, Panaretakis T, Shoshan MC, Int J Cancer 2008 123 2 476 483 (Pubitemid 351842036)
13. Tavassoéli F, Devilee P, World Health Organization Classification of Tumours Lyon: IARC Press 2003
14. HSP60 predicts survival in advanced serous ovarian cancer. Hjerpe E, Egyhazi S, Carlson J, Frostvik Stolt M, Shedvins K, Johansson H, Shoshan M, Åvall-Lundqvist E, Int J Gynecol Cancer 2013 23 3 448 455
15. Ascitic complement system in ovarian cancer. Bjorge L, Hakulinen J, Vintermyr OK, Jarva H, Jensen TS, Iversen OE, Meri S, Br J Cancer 2005 92 5 895 905 (Pubitemid 40462637)
16. Nonparametric estimation from incomplete observations. Kaplan EL, Meier P, J Am Stat Assoc 1958 53 457 481
17. Regression models and life tables. Cox DR, J R Stat Soc B 1972 34 187 220
18. Novel insight into the role of GAPDH playing in tumor. Guo C, Liu S, Sun M-Z, Clin Transl Oncol 2013 15 3 167 172
19. Glyceraldehyde-3-phosphate dehydrogenase gene expression in human breast cancer. Révillion F, Pawlowski V, Hornez L, Peyrat JP, Eur J Cancer 2000 36 8 1038 1042 (Pubitemid 30316430)
20. Expression of β-F1-ATPase and mitochondrial transcription factor A and the change in mitochondrial DNA content in colorectal cancer: clinical data analysis and evidence from an in vitro study. Lin P-C, Lin J-K, Yang S-H, Wang H-S, Li A-Y, Chang S-C, Int J Colorectal Dis 2008 23 12 1223 1232
21. Targeting Therapy for Breast Carcinoma by ATP Synthase Inhibitor Aurovertin B. Huang T-C, Chang H-Y, Hsu C-H, Kuo W-H, Chang K-J, Juan H-F, J Proteome Res 2008 7 4 1433 1444
22. Metabolic approaches to overcoming chemoresistance in ovarian cancer. Suh DH, Kim M-K, No JH, Chung HH, Song YS, Ann N Y Acad Sci 2011 1229 1 53 60
23. Pyruvate Kinase M2: Multiple Faces for Conferring Benefits on Cancer Cells. Tamada M, Suematsu M, Saya H, Clin Cancer Res 2012 18 20 5554 5561
24. The diverse functions of GAPDH: Views from different subcellular compartments. Tristan C, Shahani N, Sedlak TW, Sawa A, Cell Signal 2011 23 2 317 323
25. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. Li S-L, Ye F, Cai W-J, Hu H-D, Hu P, Ren H, Zhu F-F, Zhang D-Z, J Cell Biochem 2010 109 4 625 633
26. Down-regulation of Mitochondrial F1F0-ATP Synthase in Human Colon Cancer Cells with Induced 5-Fluorouracil Resistance. Shin Y-K, Yoo BC, Chang HJ, Jeon E, Hong S-H, Jung M-S, Lim S-J, Park J-G, Cancer Res 2005 65 8 3162 3170 (Pubitemid 40524597)
27. Gene expression analysis identifies two groups of ovarian high-grade serous carcinomas with different prognosis. Espinosa I, Catasus L, Canet B, D'Angelo E, Munoz J, Prat J, Mod Pathol 2011 24 6 846 854